Mary Kathryn Edwards
Family · Monroe, LANPI 1174096853
Payments from drug & device makers
Across 347 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$889
- Bayer$638
- Novo Nordisk$576
- AstraZeneca$524
- Lilly USA, LLC$473
- GSK$288
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,882100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $889 |
| Bayer | 39 | $638 |
| Novo Nordisk | 36 | $576 |
| AstraZeneca | 26 | $524 |
| Lilly USA, LLC | 28 | $473 |
| GSK | 14 | $288 |
| Amgen | 12 | $209 |
| Astellas Pharma US Inc | 11 | $193 |
| Esperion Therapeutics, Inc. | 13 | $191 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $176 |
| Pfizer | 10 | $173 |
| Otsuka America Pharmaceutical, Inc. | 9 | $169 |
| Kowa Pharmaceuticals America, Inc. | 9 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $127 |
| Novartis | 6 | $113 |
| Merck | 6 | $111 |
| Idorsia Pharmaceuticals US Inc | 7 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $98 |
| Exact Sciences | 5 | $97 |
| Boehringer Ingelheim | 4 | $77 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Phathom Pharmaceuticals, Inc. | 2 | $55 |
| Ironwood Pharmaceuticals, Inc | 2 | $34 |
| Ardelyx, Inc. | 2 | $34 |
| Evoke Pharma, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Abbott | 1 | $21 |
| Biogen | 1 | $19 |
| Tonix Medicines, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Johnson & Johnson | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $13 |
How this compares
$5,882 in reported general payments places this provider in the 90th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 96 | $151,994 |
| OzempicSemaglutide | 45 | $51,779 |
| FarxigaDapagliflozin Propanediol | 53 | $48,042 |
| EliquisApixaban | 45 | $43,852 |
| JardianceEmpagliflozin | 30 | $40,015 |
| VraylarCariprazine Hcl | 24 | $35,576 |
| KerendiaFinerenone | 37 | $29,865 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $21,989 |
| GlyxambiEmpagliflozin/Linagliptin | 20 | $19,829 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $16,986 |
| Repatha SureclickEvolocumab | 24 | $13,829 |
| JanuviaSitagliptin Phosphate | 12 | $8,603 |
| LinzessLinaclotide | 11 | $8,562 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,594 |
| Gabapentin | 367 | $5,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $473 | $151,99496 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $524 | $69,03092 claims |
| Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat | $77 | $65,43762 claims |
| Novo NordiskOzempic | $576 | $51,77945 claims |
| AbbVieVraylar, Linzess | $889 | $44,13835 claims |
| PfizerEliquis | $173 | $43,85245 claims |
| BayerKerendia | $638 | $29,86537 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $288 | $26,54839 claims |
| MerckJanuvia | $111 | $8,60312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,610 family providers in Louisiana.
Other family in Monroe
- Rebecca HoodMonroe$15K
- Gabrielle NicolleMonroe$14K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.